HUP9900313A1 - Antiösztrogének alkalmazása hím nemzőképesség szabályozására - Google Patents

Antiösztrogének alkalmazása hím nemzőképesség szabályozására

Info

Publication number
HUP9900313A1
HUP9900313A1 HU9900313A HUP9900313A HUP9900313A1 HU P9900313 A1 HUP9900313 A1 HU P9900313A1 HU 9900313 A HU9900313 A HU 9900313A HU P9900313 A HUP9900313 A HU P9900313A HU P9900313 A1 HUP9900313 A1 HU P9900313A1
Authority
HU
Hungary
Prior art keywords
compounds
oestrogens
steroid
receptor antagonists
estrogen receptor
Prior art date
Application number
HU9900313A
Other languages
English (en)
Inventor
Ursula-Friederike Habenicht
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of HUP9900313A1 publication Critical patent/HUP9900313A1/hu
Publication of HUP9900313A3 publication Critical patent/HUP9900313A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A jelen találmány tárgya antiösztrőgének alkalmazása hím nemzőképességszabályőzására használható gyógyszerkészítmény előállítására. Atalálmány értelmében antiösztrőgén hatású vegyületekként mind akőmpetitív antiösztrőgének (ösztrőgén-receptőr antagőnisták), mind azarőmatázgátlók szóba jönnek. A jelen találmány szerinti ösztrőgén-receptőr antagőnisták és arőmatázgátlók egyaránt lehetnekszterőidőkból levezetett vegyületek vagy nemszterőid vegyületek. Akészít- mények töbek között őrális adagőlásra alkalmas tablettákfőrmájában vagy nyújtőtt hatású alakban is előállíthatók. ŕ
HU9900313A 1995-03-16 1996-03-15 Use of anti-oestrogens as male contraceptives HUP9900313A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19510862A DE19510862A1 (de) 1995-03-16 1995-03-16 Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle

Publications (2)

Publication Number Publication Date
HUP9900313A1 true HUP9900313A1 (hu) 1999-06-28
HUP9900313A3 HUP9900313A3 (en) 1999-11-29

Family

ID=7757669

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900313A HUP9900313A3 (en) 1995-03-16 1996-03-15 Use of anti-oestrogens as male contraceptives

Country Status (21)

Country Link
US (1) US20010056086A1 (hu)
EP (1) EP0814803B1 (hu)
JP (1) JPH11501648A (hu)
KR (1) KR19980703057A (hu)
CN (1) CN1151792C (hu)
AT (1) ATE342055T1 (hu)
CA (1) CA2215373A1 (hu)
CZ (1) CZ293771B6 (hu)
DE (2) DE19510862A1 (hu)
DK (1) DK0814803T3 (hu)
ES (1) ES2275273T3 (hu)
HU (1) HUP9900313A3 (hu)
IL (1) IL117515A (hu)
NO (1) NO974256L (hu)
NZ (1) NZ303672A (hu)
PL (1) PL186085B1 (hu)
PT (1) PT814803E (hu)
SK (1) SK284442B6 (hu)
TW (1) TW503106B (hu)
WO (1) WO1996028154A2 (hu)
ZA (1) ZA962176B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
EP2258375A1 (de) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratriene

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213328A1 (de) * 1982-04-06 1983-10-06 Schering Ag 3,4,17-trioxygenierte 4,9(11)-androstadiene
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5166201A (en) * 1990-11-30 1992-11-24 Merrell Dow Pharmaceuticals Inc. 2β,19-ethylene bridged steroids as aromatase inhibitors
FR2685332A1 (fr) * 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.

Also Published As

Publication number Publication date
DE19510862A1 (de) 1996-09-19
IL117515A0 (en) 1996-07-23
WO1996028154A3 (de) 1997-05-01
IL117515A (en) 2003-07-31
AU713467B2 (en) 1999-12-02
EP0814803B1 (de) 2006-10-11
MX9707008A (es) 1997-11-29
ATE342055T1 (de) 2006-11-15
ES2275273T3 (es) 2007-06-01
PL186085B1 (pl) 2003-10-31
KR19980703057A (ko) 1998-09-05
CZ285297A3 (en) 1997-12-17
PL322253A1 (en) 1998-01-19
CN1151792C (zh) 2004-06-02
TW503106B (en) 2002-09-21
CA2215373A1 (en) 1996-09-19
DK0814803T3 (da) 2007-02-19
NZ303672A (en) 2000-07-28
NO974256D0 (no) 1997-09-15
HUP9900313A3 (en) 1999-11-29
ZA962176B (en) 1996-07-29
WO1996028154A2 (de) 1996-09-19
AU5004696A (en) 1996-10-02
JPH11501648A (ja) 1999-02-09
US20010056086A1 (en) 2001-12-27
CZ293771B6 (cs) 2004-07-14
DE59611391D1 (de) 2006-11-23
SK123897A3 (en) 1998-02-04
EP0814803A2 (de) 1998-01-07
PT814803E (pt) 2007-02-28
SK284442B6 (sk) 2005-04-01
NO974256L (no) 1997-11-14
CN1178463A (zh) 1998-04-08

Similar Documents

Publication Publication Date Title
DE69940674D1 (de) Orale verabreichung von adenosin analogen
NO20014859D0 (no) Raskt dispergerbare doseringsformer inneholdende fiskegelatin
DE69615704T2 (de) Bioadhesive feste arzneimittelform
KR900701325A (ko) 속방성 구강 투여용 정제
HUP0102913A2 (hu) Biogén ösztrogén-szulfamátok alkalmazása hormonhelyettesítő terápiánál használható gyógyszerkészítmények előállítására
KR860002270A (ko) 니트렌디핀을 함유하는 고상 약제 및 그의 제조방법
BR9509478A (pt) Antagonistas da progesterona competitivos para o controle de fertilidade feminina orientada de acordo com a necessidade
HUP0100171A2 (hu) Endotelin-receptor-antagonisták alkalmazása elhízás leküzdésére szolgáló gyógyszerkészítmények előállítására
HUP9900313A1 (hu) Antiösztrogének alkalmazása hím nemzőképesség szabályozására
KR870002845A (ko) 식욕조절 및 위암억제용 조성물
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények
HUP9802929A2 (hu) Allil-amin-származékok alkalmazása Helicobacter pylori fertőzés, valamint a fertőzéssel összefüggő betegségek kezelésére felhasználható gyógyszerkészítmények előállítására
Neto et al. lnitial experience with oxypyrantel in whipwonn infection
James Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive
UA50814C2 (uk) Анальгетичний лікарський засіб
BR0008065A (pt) Derivados de colestano insaturados e seu uso para a preparação de medicamentos que regulam meiose